Caubet Jorge, Ramis Joana M, Ramos-Murguialday Mikel, Morey Miguel Á, Monjo Marta
Bone regeneration and Oral and Maxillofacial Surgery Unit (GBCOM), Palma de Mallorca, Spain.
Clin Oral Implants Res. 2015 Jun;26(6):727-35. doi: 10.1111/clr.12380. Epub 2014 Mar 31.
Although the clinical success of Bio-Oss(®) and BoneCeramic(®) has been corroborated by histologic and histomorphometric findings, the biological events that occur during healing after maxillary sinus floor elevation (MSFE) are unknown. Here, we evaluated biopsies of grafted bone with a mixture of autologous bone and Bio-Oss(®) or BoneCeramic(®) after two different healing time periods to understand the molecular process underlying bone formation after MSFE.
Seven patients, following a bilateral split-mouth design model and needing a MSFE to allow implant placement, were recruited for this study. Right or left sinuses were grafted with autologous maxillary bone combined either with Bio-Oss(®) or BoneCeramic(®) , respectively. Twenty biopsies were taken at the time of implant insertion after 4-5 months or 6-8 months of MSFE, and analyzed by micro-computed tomography (microCT) and gene-expression analysis.
MicroCT analysis revealed no differences in the morphometric parameters or BMD either after 4-5 months or 6-8 months of MSFE between Bio-Oss(®) and BoneCeramic(®) . At molecular level, a higher expression of bone forming gene Runx2 was observed after 4-5 months of MSFE in the Bio-Oss(®) compared with the BoneCeramic(®) group.
Our results indicate that differences found at the molecular level between Bio-Oss(®) and BoneCeramic(®) are not translated to important differences in the 3D microstructure and BMD of the grafted bone.
尽管Bio-Oss(®)和BoneCeramic(®)在临床上的成功已得到组织学和组织形态计量学结果的证实,但上颌窦底提升术(MSFE)后愈合过程中发生的生物学事件尚不清楚。在此,我们评估了在两个不同愈合时间段后,使用自体骨与Bio-Oss(®)或BoneCeramic(®)混合的移植骨活检样本,以了解MSFE后骨形成的分子过程。
本研究招募了7例患者,采用双侧分口设计模型,需要进行MSFE以允许植入种植体。分别在上颌窦的右侧或左侧植入自体上颌骨,并分别与Bio-Oss(®)或BoneCeramic(®)联合使用。在MSFE后4 - 5个月或6 - 8个月植入种植体时,获取20份活检样本,并通过微计算机断层扫描(microCT)和基因表达分析进行分析。
MicroCT分析显示,在MSFE后4 - 5个月或6 - 8个月,Bio-Oss(®)和BoneCeramic(®)之间的形态计量学参数或骨密度均无差异。在分子水平上,与BoneCeramic(®)组相比,MSFE后4 - 5个月时,Bio-Oss(®)组中骨形成基因Runx2的表达更高。
我们的结果表明,Bio-Oss(®)和BoneCeramic(®)在分子水平上的差异并未转化为移植骨三维微观结构和骨密度的重要差异。